Related references
Note: Only part of the references are listed.First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor
Timothy Chow et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)
Classical Complement Pathway Inhibition in a Human-On-A-Chip Model of Autoimmune Demyelinating Neuropathies
John W. Rumsey et al.
ADVANCED THERAPEUTICS (2022)
Sutimlimab in Cold Agglutinin Disease
Alexander Roeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjorn Berentsen
FRONTIERS IN IMMUNOLOGY (2020)
Hereditary Angioedema
Paula J. Busse et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical promise of next-generation complement therapeutics
Dimitrios C. Mastellos et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease
Kenichi Makishima et al.
ANNALS OF HEMATOLOGY (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Johann Bartko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies
Anika Kasprick et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Alexander Roeth et al.
BLOOD ADVANCES (2018)
Complement in clinical medicine: Clinical trials, case reports and therapy monitoring
Daniel Ricklin et al.
MOLECULAR IMMUNOLOGY (2017)
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study
M. Wahrmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor
Ellinor I. B. Peerschke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Cold agglutinin disease
Sigbjorn Berentsen
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi et al.
BLOOD (2014)
THP-1 cell line: An in vitro cell model for immune modulation approach
Wasaporn Chanput et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia
Diana Wouters et al.
BLOOD (2013)
Biological activities of C1 inhibitor
Alvin E. Davis et al.
MOLECULAR IMMUNOLOGY (2008)
Complement before molecular biology
P Lachmann
MOLECULAR IMMUNOLOGY (2006)
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA
MA Seelen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
C1s, the protease messenger of C1 -: Structure, function and physiological significance
P Gál et al.
IMMUNOBIOLOGY (2002)
Advances in immunology: Complement (Second of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
